The therapeutic landscape for aHCC has evolved in recent years, necessitating a comprehensive analysis of treatment patterns, clinical outcomes, HCRU, and costs to contextualize emerging treatments. This study aimed to investigate these outcomes using real-world data from Ontario, Canada. This retrospective cohort study was conducted using linked administrative databases from April 2010 to March 2020. Patients diagnosed with aHCC were included, and their clinical and demographic characteristics were analyzed, as well as treatment patterns, survival, HCRU, and economic burden. Among 7322 identified patients, 802 aHCC patients met the eligibility criteria for inclusion in the study. Treatment subgroups included 1L systemic therapy (53.2%), other systemic treatments (4.5%), LRT (9.0%), and no treatment (33.3%). The median age was 66 years, and the majority were male (82%). The mOS for the entire cohort from diagnosis was 6.5 months. However, patients who received 1L systemic therapy had an mOS of 9.0 months, which was significantly higher than the other three subgroups. The mean cost per aHCC-treated patient was $49,640 CAD, with oral medications and inpatient hospitalizations as the largest cost drivers. The results underscore the need for the continuous evaluation and optimization of HCC management strategies in the era of evolving therapeutic options.
近年来，晚期肝细胞癌（aHCC）的治疗格局不断演变，亟需对治疗模式、临床结局、医疗资源使用（HCRU）及费用进行全面分析，以评估新兴治疗方案的临床价值。本研究旨在利用加拿大安大略省的真实世界数据探究上述结局指标。这项回顾性队列研究基于2010年4月至2020年3月期间关联的行政数据库开展。研究纳入确诊的aHCC患者，分析其临床与人口学特征、治疗模式、生存状况、医疗资源使用及经济负担。在7322例确诊患者中，802例aHCC患者符合研究纳入标准。治疗亚组包括一线系统治疗（53.2%）、其他系统治疗（4.5%）、局部区域治疗（9.0%）和未接受治疗（33.3%）。患者中位年龄为66岁，男性占主导（82%）。全队列自诊断起的中位总生存期（mOS）为6.5个月。然而，接受一线系统治疗患者的mOS达9.0个月，显著高于其他三个亚组。每例接受治疗的aHCC患者平均费用为49,640加元，其中口服药物和住院治疗是主要费用构成。研究结果提示，在治疗选择不断演进的时代，需要持续评估和优化肝细胞癌的管理策略。
肿瘤(癌症)患者之家